Startseite>>PSB-1115 (potassium salt)

PSB-1115 (potassium salt)

Katalog-Nr.GC44733

PSB-1115 is an antagonist of the adenosine A2B receptor (Ki = 53.4 nM).

Products are for research use only. Not for human use. We do not sell to patients.

PSB-1115 (potassium salt) Chemische Struktur

Cas No.: 409344-71-4

Größe Preis Lagerbestand Menge
5mg
111,00 $
Auf Lager
10mg
213,00 $
Auf Lager
25mg
473,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 1 publications

Description Chemical Properties Product Documents Related Products

PSB-1115 is an antagonist of the adenosine A2B receptor (Ki = 53.4 nM). [1]  It is selective for A2B over A1 and A2A receptors, which have Ki values of 2,200 and 24,000 nM, respectively, and over the A3 receptor, which it inhibits only 14% at a concentration of 10 µM. PSB-1115 pre-treatment reduces relaxation of rat trachea induced by repeated dosing of the non-selective adenosine agonist NECA .[2]

Reference:
[1]. Hayallah, A.M., Sandoval-Ramírez, J., Reith, U., et al. 1,8-Disubstituted xanthine derivatives: Synthesis of potent A2B-selective adenosine receptor antagonists. J. Med. Chem. 45(7), 1500-1510 (2002).
[2]. Walaschewski, R., Begrow, F., and Verspohl, E.J. Impact and benefit of A2B-adenosine receptor agonists for the respiratory tract: Mucociliary clearance, ciliary beat frequency, trachea muscle tonus and cytokine release. J. Pharm. Pharmacol. 65(1), 123-132 (2013).

Bewertungen

Review for PSB-1115 (potassium salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 24 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PSB-1115 (potassium salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.